Verrucous hemangioma.

reported to be as high as 69%.[1] Common cutaneous adverse effects include maculopapular eruptions and erythematous eruptions. Toxic epidermal necrolysis, Stevens–Johnson syndrome and acute generalized exanthematous pustulosis have also been reported with the use of imatinib. Other reported cutaneous adverse effects include: hypopigmentation, lichenoid reactions, pityriasiform eruptions, purpuric vasculitis, mycosis fungoides-like reactions, pityriasis rosea, psoriasis, reactivation or induction of porphyria cutanea tarda, neutrophilic eccrine hidradenitis, Sweet’s syndrome and erythema nodosum.[1]